| Primary |
| Diffuse Large B-cell Lymphoma |
20.6% |
| Chemotherapy |
16.2% |
| Product Used For Unknown Indication |
15.0% |
| Neutropenia |
13.0% |
| Drug Use For Unknown Indication |
5.9% |
| B-cell Lymphoma |
5.1% |
| Breast Cancer |
3.6% |
| Peripheral Blood Stem Cell Apheresis |
3.2% |
| Prophylaxis |
3.1% |
| Hepatitis C |
2.7% |
| Blood Stem Cell Harvest |
2.5% |
| Myelodysplastic Syndrome |
1.3% |
| Malignant Lymphoid Neoplasm |
1.1% |
| Hypertension |
1.1% |
| Agranulocytosis |
1.1% |
| Non-hodgkin's Lymphoma |
1.1% |
| Haematopoietic Stem Cell Mobilisation |
0.9% |
| Anaemia |
0.9% |
| Pre-existing Disease |
0.9% |
| Acute Myeloid Leukaemia |
0.8% |
|
| White Blood Cell Count Decreased |
11.8% |
| Death |
11.3% |
| Neutropenia |
8.0% |
| Febrile Neutropenia |
7.8% |
| Drug Ineffective |
7.4% |
| Pyrexia |
7.1% |
| Vomiting |
5.0% |
| White Blood Cell Count Increased |
4.3% |
| Bone Pain |
4.1% |
| Injection Site Pain |
3.9% |
| Pain |
3.9% |
| Therapeutic Response Decreased |
3.5% |
| Neutrophil Count Decreased |
3.1% |
| Thrombocytopenia |
3.1% |
| Pneumonia |
2.9% |
| Sepsis |
2.8% |
| Pain In Extremity |
2.7% |
| Rash |
2.7% |
| Urticaria |
2.3% |
| Acute Myeloid Leukaemia |
2.2% |
|
| Secondary |
| Diffuse Large B-cell Lymphoma |
34.2% |
| Product Used For Unknown Indication |
13.2% |
| Drug Use For Unknown Indication |
7.5% |
| Acute Myeloid Leukaemia |
6.8% |
| Prophylaxis |
6.7% |
| Chemotherapy |
4.6% |
| Breast Cancer |
2.8% |
| B-cell Lymphoma |
2.7% |
| Malignant Lymphoid Neoplasm |
2.4% |
| Hodgkin's Disease |
2.2% |
| Non-hodgkin's Lymphoma |
2.2% |
| Neutropenia |
2.0% |
| Hepatitis C |
1.9% |
| Infection Prophylaxis |
1.8% |
| Constipation |
1.6% |
| Burkitt's Lymphoma |
1.6% |
| Pain |
1.5% |
| Acute Lymphocytic Leukaemia |
1.4% |
| Peripheral T-cell Lymphoma Unspecified |
1.4% |
| Hypertension |
1.4% |
|
| Febrile Neutropenia |
11.8% |
| White Blood Cell Count Decreased |
10.8% |
| Pyrexia |
8.8% |
| Pneumonia |
6.8% |
| Vomiting |
6.1% |
| Neutropenia |
5.8% |
| Thrombocytopenia |
5.6% |
| Death |
5.4% |
| Pulmonary Fibrosis |
4.1% |
| Hyperbilirubinaemia |
3.7% |
| Sepsis |
3.7% |
| Diarrhoea |
3.6% |
| Pulmonary Embolism |
3.6% |
| Septic Shock |
3.5% |
| Gastric Ulcer Haemorrhage |
3.3% |
| Dehydration |
2.9% |
| Erysipelas |
2.7% |
| Petechiae |
2.7% |
| Syncope |
2.7% |
| Bone Pain |
2.5% |
|
| Concomitant |
| Drug Use For Unknown Indication |
24.1% |
| Product Used For Unknown Indication |
17.2% |
| Prophylaxis |
8.5% |
| Multiple Myeloma |
8.4% |
| Breast Cancer |
4.5% |
| Diffuse Large B-cell Lymphoma |
4.3% |
| Neutropenia |
3.6% |
| Hepatitis C |
3.4% |
| Pain |
3.3% |
| Hypertension |
3.0% |
| Nausea |
2.7% |
| Acute Myeloid Leukaemia |
2.6% |
| Infection Prophylaxis |
2.2% |
| Non-small Cell Lung Cancer |
2.1% |
| Prophylaxis Against Graft Versus Host Disease |
2.0% |
| Premedication |
1.8% |
| Anaemia |
1.6% |
| Aplastic Anaemia |
1.6% |
| Chronic Lymphocytic Leukaemia |
1.5% |
| Bone Marrow Conditioning Regimen |
1.5% |
|
| White Blood Cell Count Decreased |
14.1% |
| Thrombocytopenia |
10.2% |
| Vomiting |
9.7% |
| Sepsis |
8.2% |
| Neutropenia |
6.4% |
| Febrile Neutropenia |
6.0% |
| Death |
5.7% |
| Pyrexia |
5.4% |
| Weight Decreased |
5.2% |
| Septic Shock |
3.7% |
| Pneumonia |
3.3% |
| Renal Failure Acute |
2.9% |
| White Blood Cell Count Increased |
2.5% |
| Platelet Count Decreased |
2.5% |
| Acute Myeloid Leukaemia |
2.4% |
| Weight Increased |
2.4% |
| Pancytopenia |
2.4% |
| Renal Failure |
2.4% |
| Respiratory Failure |
2.4% |
| Myelodysplastic Syndrome |
2.3% |
|
| Interacting |
| Hepatitis C |
36.4% |
| Chronic Lymphocytic Leukaemia |
27.3% |
| White Blood Cell Count Decreased |
18.2% |
| Sarcoma |
9.1% |
| Unevaluable Event |
9.1% |
|
| White Blood Cell Count Decreased |
40.0% |
| Drug Interaction |
20.0% |
| Dyspnoea |
20.0% |
| Oral Herpes |
20.0% |
|
